PFE Pfizer Inc. - Fundamental Analysis

Pfizer (PFE) trades at a significant discount to peers on valuation, supported by a high 6.86% dividend yield and solid profitability metrics including a 74.81% gross margin and 35.28% operating margin. However, the company faces meaningful headwinds with declining revenue (-5.90% YoY) and earnings (-21.30% YoY), weak earnings surprise history (0/4 beats last four quarters), and a stretched payout ratio of 99.42%, raising sustainability concerns. Price momentum has improved recently (+13.6% over 6M), but long-term performance remains weak (-38.6% over 3Y), reflecting post-pandemic normalization challenges. Analysts maintain a 'buy' recommendation with a $28.96 target, implying ~15.5% upside, though this is contingent on successful pipeline execution and stabilization in core business lines.